Starlink Update: 10K Users Reached

By Ray BlancoPosted February 11, 2021

Right now 10,000 users worldwide are using the beta of Starlink’s satellite internet. And with Starlink now offering a $99 signup fee, that number could explode in the coming months.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication(s) below and get access today!

Technology Profits Confidential

With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.

Technology Profits Confidential Pro

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco

“Armed Antibody” Company Launches New Clinical Trial Programs

By Ray BlancoPosted August 15, 2014

This company launched the first new therapy for Hodgkin lymphoma in many years using an all-new biotech platform of “armed antibodies.” By combining the targeting ability of antibodies (used by our own immune systems to take out invaders) with powerful chemotherapy drugs, one of our companies made history. But I don't love this company just for creating a new cure for a cancer I once had. It just has so much going for it for a long-term investor. It’s much more than a one-hit wonder. It has something that I love when I look for a biotechnology company in which to invest. Not only does it have a breakthrough platform technology, it also has a broad pipeline of new drugs in development with the promise of delivering growing revenues in the years ahead.

This Undervalued Cancer Company Turns Into a Quick Gainer — There’s More to Come

By Ray BlancoPosted January 30, 2015

In an alert last month, I told you it was time to buy this biotech company. The company had sold off some 50% based on news that a partnered breast cancer drug hadn't showed superiority as a first-line therapy.

Big Blue Makes Big Moves

By Ray BlancoPosted September 13, 2019

Our global technology blue-chip is moving across the Atlantic to bring Europe the first-of-its-kind quantum innovation across the continent. This could revolutionize European technology!

Biotech Progress Reports From NewLink Genetics and Isis Pharmaceuticals

By Ray BlancoPosted April 5, 2013

I hope you’ve enjoyed the holiday. Coming back to nonholiday reality, the “consensus” is that things are going poorly in the world, indeed. Internationally, North Korea is throwing one of its periodic temper tantrums and issuing its usual threats, heightening tensions in an economically and politically important part of the world. Domestically, things aren’t sounding...

Update From Recent Trip, and a Sell Recommendation

By Ray BlancoPosted September 14, 2012

I spent most of Tuesday on a road trip to Miami with Patrick. While there, we visited Frank Jaksch, CEO of ChromaDex Corp., at the former IVAX Corp. building. If you recall, IVAX is now part of Teva Pharmaceuticals, and Dr. Phillip Frost, Teva's chairman, keeps his offices there. ChromaDex specializes in phytochemicals, or plant-based compounds. It provides laboratory-grade phytochemicals to academic researchers, and it also sells its own retail dietary supplements.

Verizon Flips the Wealth Switch — We Are Set to Profit

By Ray BlancoPosted October 5, 2018

We haven’t seen anything this big happen since the internet took off, or when wireless communications made smartphones possible. Find out what the all the fuss is about, and how you can make huge profits…